President Trump has been diagnosed with a minor vein condition known as chronic venous insufficiency after he noticed ...

The clinical histories disclosed that systemic lupus erythematosus may have its onset as a pulmonary problem, but involvement of the respiratory system generally occurred during the illness.

Menopause status, especially early menopause, impacts systemic sclerosis presentation, increasing risks for vascular and ...

Investigational interstitial lung disease (ILD) drug, efzofitimod, shows early signs of efficacy in patients with pulmonary ...

A systemic sclerosis-related pulmonary hypertension diagnosis in the last 10 years vs. 10 years prior was linked to improved survival. It also showed better baseline hemodynamic characteristics.

Genentech’s Actemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung ...

Infliximab and efzofitimod may be effective in pulmonary sarcoidosis and tofacitinib and adalimumab in cutaneous sarcoidosis.

While roflumilast was developed to target the pulmonary inflammation characteristic of COPD, the systemic PDE4 inhibition achieved with orally administered roflumilast may have significant anti ...

Systemic sclerosis (SSc) is a disabling autoimmune disorder that can cause diffuse fibrosis and vascular abnormalities in the skin, joints, and internal organs. Affecting approximately 2 million ...

Nevertheless, there is some evidence that the systemic anti-inflammatory effects of roflumilast may not be shared by other commonly used treatments for COPD.